Apollo Hospitals Enterprise Limited has successfully completed the full acquisition of its subsidiary Apollo Health And Lifestyle Limited by purchasing the remaining minority stake. The healthcare giant acquired 775,744 equity shares from existing individual shareholders, achieving 100% ownership of the wellness-focused subsidiary.

Acquisition Details

The transaction involved Apollo Hospitals purchasing the outstanding minority stake for a total consideration of Rs 18.69 crore. The acquisition was executed at a price of Rs 241 per share for equity shares of Rs 10 each, representing the valuation at which the final minority shareholders exited their investment.

Regulatory Disclosure

The company made the disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015. This acquisition follows previous acquisitions from International Finance Corporation and IFC EAF Apollo Investment Company, which had increased Apollo Hospitals' effective shareholding in Apollo Health And Lifestyle Limited to 99.42%.

Strategic Significance

This acquisition marks the completion of Apollo Hospitals' consolidation strategy for Apollo Health And Lifestyle Limited. By securing 100% ownership, the parent company now has complete operational and strategic control over the subsidiary's health and wellness operations. The move aligns with Apollo Hospitals' broader strategy of strengthening its integrated healthcare ecosystem.

Business Impact

The full takeover of Apollo Health And Lifestyle Limited provides Apollo Hospitals with enhanced flexibility in managing the subsidiary's operations and strategic direction. Complete ownership eliminates minority shareholder considerations in decision-making processes, potentially enabling more streamlined business operations and strategic initiatives within the health and wellness segment.

Morgan Stanley has revised its outlook on Apollo Hospitals Enterprise, maintaining an Overweight rating while adjusting the target price downward. The global investment bank continues to view the healthcare major favorably despite near-term operational challenges affecting profitability metrics.

Target Price Revision and Rating

The brokerage has reduced Apollo Hospitals' target price to ₹8,833 from the previous ₹9,209, representing a cut of ₹376 per share. Despite this downward revision, Morgan Stanley maintains its Overweight rating, indicating continued confidence in the company's long-term prospects.

Key Factors Behind the Revision

MorganStanley's target price adjustment stems from several operational challenges currently impacting the healthcare network. The primary concerns include ramp-up losses from newly established hospitals, which are affecting overall EBITDA performance. Additionally, higher operating costs associated with Apollo 24/7, the company's digital healthcare platform, have contributed to margin pressures.

Earnings Impact and Outlook

The brokerage has implemented EPS downgrades of approximately 2.5-3% for the fiscal years FY27-28. This adjustment reflects the anticipated impact of current operational challenges on near-term profitability. However, Morgan Stanley notes that the revenue outlook remains intact, suggesting confidence in the company's ability to maintain growth momentum despite margin pressures.

The analysis indicates that while Apollo Hospitals faces short-term profitability challenges from expansion activities and digital platform investments, the fundamental revenue generation capacity remains strong. The Overweight rating suggests Morgan Stanley views the current operational pressures as temporary factors that do not undermine the company's long-term value proposition in India's growing healthcare sector.